(C) Wolf G Kroner 2011 - Prof. Andreas BuschBayer AG: New Stakes in Stem Cells

January 2011. Andreas Busch, responsible for Global Drug Discovery in Bayer Pharma AG (formerly Bayer HealthCare) explains why his company opted for cancer stem cells instead of pursuing regenerative medicine. A first hand account exclusively for B2Bioworld’s readers. Insights for business development with biotech companies and options for venture capital.


If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 3 pages
- Includes

Full Company License enquire here

Back to section

Related Editorial Articles

Transition: Cancer Research Translation
Christof von Kalle, Head of National Center for Tumor Diseases at Heidelberg

Make or Break Drug Discovery and Biopharma of Merck Life Science
Andrew Bulpin, currently Global Head of Merck Millipore Process Solutions on strategy and the road ahead. Includes competitive rank of Merck Life Science Division

Triggering Regenerative Functions with Transplanted Cells and Small Molecules
Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis and Scientific Director of the research site at Vitry-Alfortville

Close-up: National Center for Tumor Diseases Heidelberg
An independent and non-sponsored look by B2Bioworld Editors

Stem Cells – Failings and Deliveries
Hugh Ilyine, former longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, and interest of venture capital

Stem Cell Research Now and in the Future
Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline on company strategy and the the role of cancer stem cells

Drug Testing with Embryonic Stem Cells
David Hays on standardization issues for therapeutics

Leroy Hood: Thinking about Stem Cells Further

Stem Cells: A discovery tool and a potential therapeutic modality
Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – clarifying the concept of personalised medicine

The Myriad Way
Peter D Meldrum, CEO of the genetics company about battles on patents, cancer chips, and competitors in commercial academia

Boehringer Ingelheim: We are obliged to more and more move away from animal models
Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim and Head of Corporate Board Division Pharma Research Corporate, evaluates prospects for stem technologies

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

Systems Biology In Search of Good Questions
Walter Kolch on the approach taken by Systems Biology Ireland

Industrial Bioscience: Solutions Marketing Never Dreamt of…
Bayer CropScience: Hidden Potentials, Revaluation of IP Assets, and Substantial Changes in R&D